TORONTO, June 25 /CNW/ - Theralase Technologies Inc. (TSX-V: TLT) today announced that Michel LeBel has resigned from the Board of Directors and Andrew Szonyi has withdrawn his nomination to the Board of Directors. Both Mr. LeBel and Mr. Szonyi joined Theralase's Board in May 2006. The Company is currently looking to add members to its Board of Directors.

"We thank Michel and Andrew for their commitment to Theralase over the past two years and wish them well in the future," said Donald Moore, Chairman of Theralase's Board of Directors.

Theralase Technologies Inc. designs, develops and manufactures patented, super-pulsed laser technology used in a wide range of bio-stimulation and bio-destruction clinical applications. The Theralase technology platform targets several diverse healthcare sectors: firstly, for non-invasive pain management and clinical therapy, in hundreds of neural muscular skeletal conditions, including arthritis; secondly, to bio-stimulate and accelerate wound care and healing, including bone fracture regeneration; and thirdly, combining photodynamic compounds with super-pulsed, biofeedback laser technology to attack specifically targeted cancer, bacteria, viruses and fat cells.

This press release contains forward-looking statements which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual results could differ materially from those projected herein. The Company disclaims any obligation to update these forward-looking statements.

The TSX Venture Exchange has not reviewed and does not accept

responsibility for the adequacy or accuracy of the contents of this

release.